Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-C18S in Advanced Solid Tumors
NCT04467853Phase 1Terminated
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-C18S in solid tumor, sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity and incidence, severity, and type of treatment-emergent adverse events at 2 years, Recommended Phase 2 Dose at 90 days and 1 more. Started Sep 2020; status: terminated.
02
Drugs
LCAR-C18S
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04467853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467853.